Natural Cycles, a pioneering firm in digital health, recently secured $55 million in funding. This injection will propel its innovative birth control app, enhancing technology and expanding offerings.
The company strives to revolutionise women’s health by providing accessible, hormone-free birth control methods. With significant investor backing, Natural Cycles is set to transform the landscape of digital contraceptives.
Significant Funding Milestone
Natural Cycles has achieved a significant milestone by securing $55 million in Series C funding. This round, led by Lauxera Capital Partners, included participation from Point72 Private Investments and a revolving debt facility from J.P. Morgan. The funds are earmarked to accelerate commercial growth and develop new products, positioning Natural Cycles as a leader in women’s digital health solutions.
Pioneering Contraceptive Technology
Founded in 2013, Natural Cycles stands out as a pioneering force in womens health, offering the worlds first certified birth control app. The app, utilised by over three million users globally, is the only digital form of birth control approved in several countries, including the United States, UK, and Canada. Its algorithm determines daily fertility based on body temperature, integrating with wearables like the Oura Ring.
Expanding Product Range
Earlier this month, Natural Cycles introduced NC° Postpartum, a new feature that supports new mothers as they recover from childbirth. This addition complements existing modes such as NC° Birth Control, NC° Plan Pregnancy, and NC° Follow Pregnancy, providing robust support throughout the fertility journey. These developments highlight Natural Cycles’ commitment to enhancing women’s health solutions, addressing both physical and mental recovery needs.
Strategic Partnership
Lauxera Capital Partners, along with esteemed partners like Point72, joins the ranks of Natural Cycles’ investors, aiming to transform future medicine with technology. Samuel Levy, from Lauxera, highlighted the exceptional growth of Natural Cycles, noting the company’s unique clinical and regulatory strengths. Levys appointment to the Board of Directors signifies a deeper strategic involvement in Natural Cycles mission to provide hormone-free birth control solutions.
Strengthening Global Presence
The collaboration with Point72 and existing investors like EQT Ventures and Samsung Ventures signifies a robust support network for Natural Cycles. This backing is crucial as the company seeks to expand its market presence and push innovative boundaries in women’s health. The collective expertise and financial muscle of these investors position Natural Cycles for substantial growth and continued innovation.
Impact and Future Directions
The recent funding round not only injects capital but also propels Natural Cycles into the next phase of growth, leveraging technology to bridge gaps in women’s health. Dr. Raoul Scherwitzl, CEO, expressed enthusiasm for this progress, emphasising the company’s mission to make hormone-free birth control more accessible. This step forward underlines Natural Cycles’ commitment to transforming reproductive health through cutting-edge digital solutions.
Looking Ahead
With the substantial funding secured, Natural Cycles is poised to enhance its service offerings further and expand its customer base. The focus will remain on developing innovative, non-invasive birth control methods that cater to the modern woman’s needs. This commitment promises to redefine how women manage their reproductive health, steering away from traditional hormone-based methods.
The $55 million funding represents a pivotal moment for Natural Cycles as it continues to innovate in the women’s health sector. The focus remains on expanding global reach and product offerings.
This advancement underscores Natural Cycles’ dedication to providing non-hormonal contraceptive solutions, poised to redefine reproductive health management.
